ORG Partners LLC Buys 884 Shares of Pfizer Inc. (NYSE:PFE)

ORG Partners LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 1.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,912 shares of the biopharmaceutical company’s stock after acquiring an additional 884 shares during the period. ORG Partners LLC’s holdings in Pfizer were worth $1,387,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Olistico Wealth LLC purchased a new position in shares of Pfizer in the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $29,000. Quarry LP acquired a new position in Pfizer during the second quarter worth about $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer during the fourth quarter worth about $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its position in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Pfizer stock traded down $0.17 during mid-day trading on Monday, reaching $28.99. The company’s stock had a trading volume of 5,914,628 shares, compared to its average volume of 37,234,906. The firm has a market cap of $164.27 billion, a price-to-earnings ratio of -483.33, a PEG ratio of 1.30 and a beta of 0.67. The business has a 50 day moving average price of $29.04 and a 200-day moving average price of $28.39. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $33.92.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the business earned $0.67 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.80%. Pfizer’s payout ratio is presently -2,800.00%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Barclays lifted their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Thursday, October 3rd. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.